Ellipsis Health is a technology company.
Ellipsis Health has raised $75.0M across 3 funding rounds.
Ellipsis Health has raised $75.0M in total across 3 funding rounds.
# High-Level Overview
Ellipsis Health is an AI healthcare company that uses voice biomarker technology to transform mental health screening and care management.[1][7] The company has developed Sage, an emotionally intelligent AI voice agent that generates assessments of stress, depression, and anxiety from less than 60 seconds of natural speech, enabling healthcare providers and payers to identify patients who need mental health support more quickly and efficiently.[3][6]
The company serves a critical gap in the healthcare system: while over one in five Americans suffer from mental illness, less than half receive mental health services.[2] Ellipsis Health addresses this through partnerships with leading healthcare organizations, payers, and employers, helping them expand capacity, reduce costs, and improve patient outcomes—particularly for underserved populations including children and adolescents.[3][6] The company's technology integrates seamlessly into existing workflows through mobile apps, patient portals, and telehealth visits, enabling data-driven care without requiring significant operational disruption.[6]
# Origin Story
Ellipsis Health was founded by Mainul Mondal (Founder & CEO), Dr. Michael Aratow (Co-Founder & Chief Medical Officer), and Susan Solinsky, with the mission to make mental health screening as reliable as physical health screening.[2][3] Mondal's personal motivation—described as "a personal struggle"—drove him to focus on the nascent mental health technology sector, ultimately building a company dedicated to democratizing accurate mental health screening by breaking down barriers such as cost, inability to attend in-person sessions, and patient backlogs.[2]
The company achieved early traction through strategic partnerships with major healthcare organizations. A notable collaboration with payor Cigna International, which began in 2021, resulted in the Cigna StressWaves Test, demonstrating the commercial viability of Ellipsis Health's voice-based screening approach.[2] By 2023, the company had secured $26 million in Series A funding (bringing total funding to $31 million), and more recently unveiled Sage with backing from Salesforce, Khosla Ventures, and CVS Ventures totaling $45 million.[6][7]
# Core Differentiators
# Role in the Broader Tech Landscape
Ellipsis Health operates at the intersection of three powerful trends: the AI-driven automation of healthcare, the mental health crisis in the United States, and the shift toward preventive, data-driven care models.
The timing is critical. With 28% of Americans experiencing depression and 36% suffering from anxiety annually, yet only 45% of those with mental illness receiving treatment, there is both urgent clinical need and significant economic incentive for solutions that improve screening and access.[3] Healthcare systems are simultaneously facing clinician shortages and rising operational costs, making AI-powered care management increasingly attractive to payers and providers seeking to maintain quality while controlling expenses.[1]
Ellipsis Health's voice biomarker approach represents a novel clinical standard—positioning voice as a "vital sign" for mental health, analogous to how blood pressure or heart rate function in physical medicine.[6] This framing has broader implications: it legitimizes mental health measurement in clinical workflows, reduces stigma, and creates a scalable, objective foundation for care decisions. The company's success influences the broader ecosystem by demonstrating that conversational AI can deliver clinical value while maintaining empathy and patient dignity.[1]
# Quick Take & Future Outlook
Ellipsis Health is well-positioned to become a foundational infrastructure layer in mental health care. The company's focus on integration with existing systems (rather than requiring wholesale adoption of new platforms) reduces barriers to adoption, while its partnerships with major payers and providers create network effects that strengthen its competitive moat.
Looking ahead, three dynamics will shape the company's trajectory: (1) regulatory validation—as voice biomarkers gain clinical acceptance and potential FDA clearance, adoption will accelerate; (2) expansion into pediatric mental health—a historically underserved segment with significant unmet need and growing parental/institutional demand; and (3) international scaling—the company's mission to establish voice as a global clinical standard suggests ambitions beyond the U.S. market.
The broader question is whether Ellipsis Health becomes a standalone category leader or a critical component acquired by a larger healthcare technology or payer platform. Either path reflects the company's core insight: technology that extends clinician capacity while preserving compassion is not just operationally efficient—it's clinically essential. In a healthcare system struggling with burnout and access gaps, that combination is increasingly rare and valuable.
Ellipsis Health has raised $75.0M in total across 3 funding rounds.
Ellipsis Health's investors include CVS Health, 01 Advisors, 8090 Industries, 8VC, Kevin Hartz, AIX Ventures, Animal Capital, Aurora Forge, Chapter One Ventures, Craft Ventures, Creandum, Edison Ventures.
Ellipsis Health has raised $75.0M across 3 funding rounds. Most recently, it raised $45.0M Series A in June 2025.